Moleculin Biotech, Inc.(MBRX)Stock Analysis

MBRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Moleculin Biotech, Inc. (MBRX), a Healthcare sector company. MBRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Moleculin Biotech, Inc. reports net income of $-12.8M, free cash flow of $-6.1M. Top institutional holders of MBRX by reported 13-F value include SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MBRX trades on the Nasdaq exchange and files with the SEC under CIK 1659617. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moleculin Biotech, Inc. directly from SEC EDGAR.